In recent years, PD-1/L1 inhibitor-containing therapies have shown unparalleled clinical efficacy and a favorable safety profile in the management of lung cancer (Steven et al., 2016; Doroshow et al., 2019). The gene discussed is PDCD1; the disease is lung carcinoma.